modelR01AA05
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Oxymetazoline | |
| ATC code: | R01AA05 | route: | intranasal |
| compartments: | 1 | |
| dosage: | 0.05 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Oxymetazoline is an imidazoline decongestant, primarily used as a topical nasal spray for temporary relief of nasal congestion due to common cold, hay fever, or allergies. It acts as an alpha-adrenergic agonist leading to vasoconstriction. Oxymetazoline is available in over-the-counter formulations and is still approved for use today.
Pharmacokinetics
There are very limited published data on the pharmacokinetic parameters of oxymetazoline in humans, especially after intranasal administration. No full pharmacokinetic profile with explicit parameters based on published population PK models is available in the literature.
References
Cacek, AT, et al., & Gopalakrishnan, M (2017). Population Pharmacokinetics of an Intranasally Administered Combination of Oxymetazoline and Tetracaine in Healthy Volunteers. Journal of clinical pharmacology 57(2) 247–254. DOI:10.1002/jcph.799 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27436060
Kaessner, N, et al., & Lahu, G (2012). Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain. International journal of clinical pharmacology and therapeutics 50(9) 665–677. DOI:10.5414/CP201737 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22784611
Cartabuke, RS, et al., & Tobias, JD (2019). Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children. The Laryngoscope 129(12) 2775–2781. DOI:10.1002/lary.27760 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30786035
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)